New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2013
09:10 EDTSTEMStemCells launches Alzheimer's program, received first disbursement of $3.8M
StemCells announced that it has formally launched its Alzheimer's disease program, which is being supported by the California Institute for Regenerative Medicine, or CIRM. The goal of the project is to file, within four years, an Investigational New Drug, or IND, application with the FDA to evaluate the company's proprietary HuCNS-SC product candidate as a potential therapeutic in the treatment of Alzheimer's disease. CIRM has agreed to provide approximately $19.3M to the company in the form of a forgivable loan to help fund preclinical development and IND-enabling activities, and the company recently received an initial disbursement of $3.8M from CIRM. The funding was awarded under CIRM's Disease Team Therapy Development Award program in September 2012.
News For STEM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
10:35 EDTSTEMStemCells appoints Ian Massey as President and COO effective March 23
Subscribe for More Information
March 16, 2015
16:23 EDTSTEMStemCells reports Q4 EPS (14c), one estimate (4c)
Reports Q4 revenue $883K vs 45K in Q413. "Total revenue from continuing operations during the fourth quarter of 2014 was $883,000, compared to $45,000 in the same period of 2013. Revenue from continuing operations is primarily from royalties and milestone payments received under various licensing agreements. The increase in 2014 was primarily attributable to a milestone payment of approximately $500,000 received under a licensing agreement with ReNeuron Ltd. and a licensing fee of approximately $400,000 in connection with our divestiture of the SC Proven business entered into with Takara Bio Inc., a publicly traded Japanese company."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use